SAE vs SUSAR vs AE: Definitions, Differences and Examples

AE is any untoward medical occurrence during drug use, whether or not drug-related. SAE is an AE with a serious outcome such as death or hospitalisation. SUSAR is a serious, suspected drug reaction that is unexpected compared with reference safety information, and it drives expedited reporting.
Readers searching for sae vs susar vs ae usually need to know which term triggers which obligation. The three terms are nested: every SUSAR is an SAE, and every SAE is an AE, but the reverse does not hold. This article gives working definitions, a comparison table, a classification example, and the reporting timelines that apply to SUSARs.
What is the difference between an AE, ADR, SAE and SUSAR?
An adverse event (AE) is any untoward medical occurrence associated with the use of a drug in humans, whether or not it is considered drug-related [1]. Causality is not part of the AE definition, so a patient who breaks a leg during a trial is still an AE. In the marketed-product context, the same idea is called an adverse drug experience, which also covers overdose, abuse and withdrawal [3].
Build These Skills Now
Programs from ZANE ProEd Academy that directly address the skill gaps discussed above.
An adverse drug reaction (ADR) is a narrower term used in general pharmacovigilance practice. It describes a response to a drug where a causal link is at least reasonable, and it is often used interchangeably with the regulatory term suspected adverse reaction. The regulatory definition is the one that matters for reporting, because it sets the threshold for what must be submitted [1].
A suspected adverse reaction is any adverse event for which there is a reasonable possibility that the drug caused it, meaning there is evidence to suggest a causal relationship [1]. A serious adverse event (SAE) is an AE or suspected adverse reaction judged serious by the investigator or sponsor, and seriousness is defined by outcome [1]. A suspected unexpected serious adverse reaction (SUSAR) combines the two: it is serious, suspected to be drug-related, and unexpected, meaning not listed in the investigator brochure at that specificity or severity [1].
| Term | Core question | Causality needed? | Expectedness needed? | Typical trigger |
|---|---|---|---|---|
| AE | Did an untoward medical occurrence happen while the patient was on the drug? | No | No | Any new symptom, lab abnormality or event reported during use |
| ADR / suspected adverse reaction | Is there a reasonable possibility the drug caused it? | Yes, at least reasonable possibility | No | Rash judged possibly related to the study drug |
| SAE | Does the event meet a seriousness outcome? | Not for SAE alone in a general sense, but needed for the suspected subset | No | Hospitalisation for any cause during the study |
| SUSAR | Is a serious suspected reaction also unexpected? | Yes | Yes | Liver injury not described in the investigator brochure |
What makes an adverse event serious?
An event is serious if, in the view of the investigator or sponsor, it results in death, a life-threatening event, inpatient hospitalisation or prolongation of existing hospitalisation, a persistent or significant disability or incapacity, or a congenital anomaly or birth defect [1]. The judgement is made by the reporting professional or sponsor, not by the regulator, and the assessment should be documented. The definition deliberately focuses on outcome rather than on how severe the event looks at first.
Life-threatening has a narrow meaning. It applies when the event places the patient at immediate risk of death as it occurred. An event that would have been fatal only if it were more severe does not qualify [1]. Disability is also specific: it means a substantial disruption of the ability to conduct normal life functions [3].
Some events are serious without any of those outcomes. Important medical events can qualify when, on medical judgement, they may jeopardise the patient and may need intervention to prevent a listed outcome. Examples in the regulation include allergic bronchospasm needing emergency treatment, blood dyscrasias or convulsions without hospitalisation, and drug dependency [1]. The ICH E2B(R3) data elements mirror these categories as separate tick-boxes: results in death, life threatening, caused or prolonged hospitalisation, disabling or incapacitating, congenital anomaly, and other medically important condition [2]. For a miscarriage, the ICSR is prepared for the parent, and the seriousness criterion is other medically important condition, possibly with life-threatening or hospitalisation added if the parent had complications [2].
Worked example: classifying one case
A 58-year-old patient in a phase III trial develops jaundice on day 20 and is admitted to hospital for five days. The investigator judges the liver injury possibly related to the study drug. The investigator brochure lists only elevated liver enzymes. Apply the steps below.
- Confirm an AE occurred during drug use. Jaundice on treatment is an AE, regardless of cause.
- Check seriousness. Inpatient hospitalisation is a listed outcome, so the event is an SAE [1][2].
- Check suspected causality. A reasonable possibility of drug causality makes it a suspected adverse reaction [1].
- Check expectedness. Liver injury is in the brochure, but jaundice at this severity is not listed, so the event is unexpected by severity [1].
- Classify. Serious, suspected and unexpected means this is a SUSAR and must enter the expedited pathway [1].
- Document the reasoning for each step, including who made the seriousness and causality judgements, so the classification can be reviewed later.
What are SUSAR reporting timelines?
For an IND, the sponsor must notify FDA and all participating investigators of a suspected adverse reaction that is both serious and unexpected. The report is due as soon as possible and in no case later than 15 calendar days after the sponsor determines that the information qualifies for reporting [1]. The clock therefore starts at the sponsor's determination, not at the date the site first learned of the event, so the determination date should be recorded precisely.
Each IND safety report must also identify previous similar reports submitted to FDA and analyse the significance of the reaction in light of them [1]. This means a SUSAR cannot be submitted as a standalone form without linking it to the existing case history. Sponsors also review all relevant safety information from foreign and domestic sources promptly [1].
For marketed products, the rules differ. Postmarketing periodic adverse drug experience reports are submitted quarterly for three years after approval and then annually, with the quarterly report due within 30 days of the quarter end and the annual report within 60 days of the approval anniversary [3]. Outside the United States, EU and ICH expedited rules use their own clocks, and the timelines for those regions should be checked against current local guidance rather than assumed to match FDA.
| Report type | Applies to | Timeline in the source passages | Source |
|---|---|---|---|
| IND safety report (SUSAR) | Serious, suspected, unexpected reactions in an IND | As soon as possible, no later than 15 calendar days after sponsor determination | [1] |
| Quarterly periodic report | Marketed product, first three years after approval | Within 30 days of quarter close | [3] |
| Annual periodic report | Marketed product, after the quarterly phase | Within 60 days of approval anniversary | [3] |
Key takeaways
- Every SUSAR is an SAE and every SAE is an AE, but an AE is not automatically serious, suspected or unexpected [1].
- Seriousness is defined by outcome or by medical judgement of jeopardy, and the investigator or sponsor makes that call [1][2].
- Causality uses a reasonable possibility threshold, and expectedness is judged against the investigator brochure or reference safety information [1].
- For an IND, a SUSAR must be reported to FDA and investigators within 15 calendar days of sponsor determination [1].
- Record determination dates and reasoning, because the timeline depends on them.
How can you practise SAE and SUSAR classification hands-on?
Reading definitions is not the same as classifying a case under time pressure. The End-to-End ICSR Case Processing Certification at ZANE ProEd is an intermediate course that includes adverse event and SAE classification, GVP foundations, MedDRA coding and submission timelines. It is a practical place to apply the steps in this article to realistic case scenarios.
Frequently asked questions
Is every serious adverse event a SUSAR?
No. An SAE becomes a SUSAR only when it is also suspected to be drug-related and unexpected. A serious event with a clear alternative cause, or one already listed in the investigator brochure at that severity, is an SAE but not a SUSAR [1].
Do non-serious adverse events need reporting?
Not on the expedited pathway described for SUSARs. Non-serious events are still recorded and reviewed in trial and safety databases, and they may feed into periodic analysis, but they do not trigger the 15-day IND clock [1][3].
Who decides whether an event is serious?
Under the FDA definition, either the investigator or the sponsor may judge an event serious, and the view of either is sufficient [1]. Sponsors should align their process so that a site judgement and a sponsor judgement are reconciled and documented.
Does the term ADR mean the same as suspected adverse reaction?
In practice they are often used interchangeably, but the regulatory text uses suspected adverse reaction for cases with a reasonable possibility of causality, and adverse reaction for cases already established as drug-caused [1]. Use the term your regulator and SOPs specify in each report.
Sources
- 21 CFR 312.32: IND safety reporting (eCFR (current)). FDA.
- ICH E2B(R3): Electronic Transmission of Individual Case Safety Reports (ICSRs): Data Elements and Message Specification (R3). ICH.
- 21 CFR 314.80: Postmarketing reporting of adverse drug experiences (eCFR (current)). FDA.
Build These Skills Now
Programs from ZANE ProEd Academy that directly address the skill gaps discussed above.
Follow Zane ProEd on Google
Preferred SourceAdd our publication as a preferred source to get the latest clinical research guides, industry updates, and career intel directly in your Google Top Stories & AI Overviews.